Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)
This study is currently recruiting participants.
Verified June 2012 by Population Health Research Institute
Sponsor:
Population Health Research Institute
Collaborator:
Hamilton Health Sciences Corporation
Information provided by (Responsible Party):
Dr. Hertzel Gerstein, Population Health Research Institute
ClinicalTrials.gov Identifier:
NCT01181674
First received: August 11, 2010
Last updated: June 7, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this pilot trial is to determine whether an intensive treatment with insulin glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients with recently diagnosed type 2 diabetes mellitus when compared to standard diabetes care.
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes Mellitus |
Drug: insulin glargine Drug: metformin Drug: acarbose Behavioral: lifestyle therapy Other: Standard glycemic care |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT): A Randomized Controlled Pilot Trial |
Resource links provided by NLM:
MedlinePlus related topics:
Diabetes
Diabetes Medicines
Diabetes Type 2
Exercise and Physical Fitness
Drug Information available for:
Metformin
Metformin hydrochloride
Insulin human
Acarbose
Insulin glargine
U.S. FDA Resources
Further study details as provided by Population Health Research Institute:
Primary Outcome Measures:
- Proportion of participants achieving normoglycemia in the experimental group 1 compared to the control group [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- Proportion of participants achieving normoglycemia in the experimental group 2 compared to the control group [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Proportion of participants with normal glucose tolerance [ Time Frame: 20 and 28 weeks ] [ Designated as safety issue: No ]
- Proportion of participants with normal fasting plasma glucose [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
- Change in fasting plasma glucose from baseline [ Time Frame: Baseline and 52 weeks ] [ Designated as safety issue: No ]
- HbA1C [ Time Frame: 8, 20, 28 and 52 weeks ] [ Designated as safety issue: No ]
- Change in weight from baseline [ Time Frame: Baseline, 8, 20, 28 and 52 weeks ] [ Designated as safety issue: No ]
- Rate of symptomatic hypoglycemic episodes [ Time Frame: 28 weeks ] [ Designated as safety issue: Yes ]
- Rate of severe hypoglycemic episodes [ Time Frame: 28 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 126 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | January 2014 |
| Estimated Primary Completion Date: | January 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Group 1 (short) |
Drug: insulin glargine
sc injection
Drug: metformin
oral administration
Drug: acarbose
oral administration
Behavioral: lifestyle therapy
diet and exercise
|
| Experimental: Group 2 (long) |
Drug: insulin glargine
sc injection
Drug: metformin
oral administration
Drug: acarbose
oral administration
Behavioral: lifestyle therapy
diet and exercise
|
| Standard care |
Other: Standard glycemic care
as informed by the current clinical practice guidelines
|
Detailed Description:
This is a pilot trial of 125 patients allocated to either usual care (1/3), 2 months or 4 months of intensive lifestyle and pharmacotherapy followed by cessation of all drug therapy.
Eligibility| Ages Eligible for Study: | 30 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- men and women 30-80 years of age inclusive
- type 2 diabetes mellitus diagnosed by a physician within 3 years prior to patient enrollment
- anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks prior to screening and randomization
- HbA1C 6.5-8% inclusive on no oral hypoglycemic agents or HbA1C ≤ 7.5% on 1 agent or on half-maximal doses of 2 agents
- body mass index ≥ 23 kg/m2
- a negative pregnancy test and an agreement to use a reliable method of birth control for the duration of the trial in all females with childbearing potential
- ability and willingness to perform self-monitoring of capillary blood glucose (SMBG)
- ability and willingness to self-inject insulin
- provision of informed consent.
Exclusion Criteria:
- current use of insulin therapy
- history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance
- renal dysfunction as evidenced by serum creatinine (Cr) ≥ 124 μmol/l
- history of lactic acidosis or diabetic ketoacidosis
- active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper limit of normal at the time of enrollment
- history of inflammatory bowel disease, colonic ulcers, recent or significant bowel surgery, or predisposition to bowel obstruction
cardiovascular disease including any of:
- systolic blood pressure >180 mmHg or diastolic blood pressure >105 mmHg
- peripheral vascular disease
- left bundle branch block or third degree AV block
- tachyarrhythmias or bradyarrhythmias with uncontrolled ventricular rate
- stenotic valvular heart disease
- cardiomyopathy
- history of heart failure
- history of aortic dissection
- documented history of angina or coronary artery disease
- history of stroke or transient ischemic attack
- pulmonary disease with dependence on oxygen
- history of any disease requiring intermittent or continuous systemic glucocorticoid treatment
- history of any major illness with a life expectancy of <3 years
- history of injury or any other condition that significantly limits participant's ability to achieve moderate levels of physical activity
- any history of excessive alcohol intake, acute or chronic
- known hypersensitivity to metformin, acarbose, or insulin glargine.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01181674
Contacts
| Contact: Hertzel Gerstein, MD | gerstein@mcmaster.ca |
Locations
| Canada, Ontario | |
| McMaster University Medical Centre, Diabetes Care and Research Program | Recruiting |
| Hamilton, Ontario, Canada, L8N 3Z5 | |
| Contact: Ada Smith 905-525-9140 ext 22205 | |
Sponsors and Collaborators
Population Health Research Institute
Hamilton Health Sciences Corporation
Investigators
| Principal Investigator: | Hertzel Gerstein, MD | Population Health Research Institute |
| Principal Investigator: | Natalia Yakubovich, MD | Population Health Research Institute |
More Information
No publications provided
| Responsible Party: | Dr. Hertzel Gerstein, Director, Division of Endocrinology and Metabolism, McMaster University, Population Health Research Institute |
| ClinicalTrials.gov Identifier: | NCT01181674 History of Changes |
| Other Study ID Numbers: | REMIT Pilot, Control # 139433, 143584, 10-346 |
| Study First Received: | August 11, 2010 |
| Last Updated: | June 7, 2012 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Population Health Research Institute:
|
Diabetes Insulin Glargine Metformin |
Acarbose Diet Exercise Lifestyle |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Glargine Insulin Metformin |
Acarbose Insulin, Long-Acting Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 16, 2013